Loading…

Sanofi SASAN.PACompetitor analysis, valuation and peers

France · EUR·Health Care›Pharmaceuticals: Major

French pharmaceutical major selling vaccines, specialty medicines (immunology, rare disease) and consumer health products.

≈ France's Pfizer/MerckMomentum leader 94
Mkt cap
$114B
US dollars, full cap
Free float
92%
of shares outstanding
$/day
$253M
20-day average traded
Fwd P/E
9.7×
forward earnings
ROIC−WACC
+3.6 pp
WACC 7.0%
Hurdle
-9 pp
Req g minus delivered
Official | Implied
AA / AAA
agencies · bond market
Close · EUR€86.25
1D-0.4%
1W-0.4%
1M+17.2%
3M+9.3%
6M+13.0%
YTD+4.3%
1Y-0.1%
ATR %1.9%
52w lowhigh3.1% off high

What Sanofi does

French pharmaceutical major selling vaccines, specialty medicines (immunology, rare disease) and consumer health products.

Dupixent, an eczema and asthma drug it develops and shares profits on with Regeneron, is the biggest growth product, while vaccines are sold largely through government and health-system purchasing. It sold a majority of its consumer-health arm, Opella, to the private-equity firm CD&R in 2025, keeping a minority stake.

In one line: France's Pfizer/Merck.

Products and services

  • Dupixent (immunology, with Regeneron)
  • Vaccines (Sanofi Pasteur)
  • Rare disease/hematology
  • Consumer healthcare (Opella)

Customers

  • Hospitals & physicians
  • Patients
  • Health systems/payers
  • Retail consumers (OTC)

Where it sits in the supply chain

  • Pharmaceuticals
  • Drug R&D & manufacturing
  • Prescription drugs, vaccines, consumer…

What could go right

  • Dupixent growth
  • Vaccine demand (flu, RSV)
  • Opella consumer health spin-off value

What could go wrong

  • Patent expirations on older drugs
  • Pricing pressure/reference pricing
  • Clinical trial failures

Moat: narrow (IP / patents, scale, regulatory licence). Patent-protected blockbusters (Dupixent) and vaccine manufacturing scale, but facing patent cliffs.

Headquarters: Paris, France · Founded: 1973 · Employees: 76,493

Named competitors

Sanofi at a glance

Size Sanofi (SAN.PA) is a France Health Care company (Pharmaceuticals: Major) with a market value of $114B, the 9th largest of 206 France companies the cockpit tracks. Shares closed at €86.25 on 18 Nov 2026.

Performance Over six months the shares gained 13.0%, against +9.1% for the median peer and -2.1% for the France market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 15.3% over the last twelve months (peer median +5.9%); the operating margin is 27.2% (peer median 24.0%).

Valuation It trades at 9.7× forward earnings against a peer median of 17.5× (2nd cheapest of 21).

Price implies For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -9 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.6 points above its cost of capital (7.0% WACC).

Credit Sanofi has 15 bonds outstanding ($14.6B), rated AA by the agencies and trading like AAA at a weighted spread of 41 bp.

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026SAN.PA 112Peer median 110
Six months, rebased to 100: Sanofi against the median of its 20 peers (local-currency closes).

Sanofi financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€45.8B€43.6B€41.1B€37.8B€43.0B
Revenue growth—+6%+9%-12%—
Gross profit€30.4B€28.7B€26.0B€23.1B€27.1B
EBITDA€19.3B€17.1B€13.1B€12.3B€13.7B
Net income€4.02B€5.20B€5.56B€5.40B€8.37B
Free cash flow€10.2B€8.99B€7.35B€8.64B€8.32B
Capital expenditure€3.49B€3.62B€3.23B€3.13B€2.22B
Total debtn/a€20.3B€17.9B€18.4B€21.2B

Quarterly statements and history in the cockpit →

Sanofi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+20%+40%0%+10%BMYGSKREGNVRTXPFE4519NOVO-BMRK4502603259BAYNGALDSUNPHARMAAZN600276688235SDZ4578HLNSAN.PA6-month return →1-month return →
Up and to the right = strong over both horizons. Sanofi is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×BMYGSKREGNVRTXPFE4519NOVO-BMRK4502603259BAYNGALDSUNPHARMAAZN600276688235NOVNSDZ4578SAN.PARevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sanofi is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%BMYGSKREGNVRTXNOVO-BMRK603259GALDSUNPHARMAAZN600276688235NOVNSAN.PAGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sanofi is the large dot.

Sanofi competitors and peer comparison

Head to head with its named competitors (SAN.PA vs PFE vs NOVN.SW vs GSK.L)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Sanofi SAN.PA$114B+13%+15%27%9.7×-4.8%
Pfizer PFE$160B+9%+1%26%9.9×-4.3%
Novartis NOVN.SW$285B+11%-4%30%17.5×1.6%
GSK GSK.L$97.9B-3%+4%25%10.4×-0.1%
Merck & MRK$340B+23%+5%18%16.4×8.3%
Roche RO.SW$381B+21%-1%31%19.9×1.7%

How Sanofi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sanofi against its 20 peers (data as of 18 Nov 2026)
MeasureSAN.PAPeer medianRank in peer set
1-month return+17.2%+4.1%2nd highest of 21
6-month return+13.0%+9.1%9th highest of 21
Distance from 52-week high-3.1%-9.7%2nd highest of 21
Revenue growth (TTM)+15.3%+5.9%6th highest of 21
Operating margin27.2%24.0%9th highest of 21
Forward P/E9.7×17.5×2nd cheapest of 21
Growth the price implies (Req g, 7 yrs)-4.8%5.2%2nd least demanding of 20
Growth delivered (Del g)+3.9%+8.5%8th lowest of 20
Hurdle (Req g minus delivered)-8.7 pp-3.4 pp8th least demanding of 20
ROIC minus cost of capital+3.6 pp+6.3 pp7th lowest of 21
EV / EBITDA6.3×13.8×cheapest of 19
Net debt / EBITDA0.9×1.3×8th least indebted of 19
Bond spread41 bp76 bptightest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sanofi SAN.PAFrance$114B+13%+15%27%9.7×-4.8%+3.9%
Bristol Myers Squibb BMYUnited States$122B+3%+4%33%9.2×-13.1%+2.5%
GSK GSK.LUnited Kingdom$97.9B-3%+4%25%10.4×-0.1%-0.9%
Regeneron Pharmaceuticals REGNUnited States$97.8B+46%+19%30%11.8×-1.1%+11.0%
Vertex Pharmaceuticals VRTXUnited States$136B+25%+11%35%28.5×6.2%+14.2%
Pfizer PFEUnited States$160B+9%+1%26%9.9×-4.3%+8.5%
Chugai Pharmaceutical 4519.TJapan$75.2B-8%+17%50%23.7×5.0%+9.8%
Novo Nordisk A/S NOVO-B.CODenmark$177B-6%+6%48%11.8×-0.5%+19.5%
Merck KGaA MRK.DEGermany$71.3B+16%+1%19%17.4×7.4%+3.8%
Takeda Pharmaceutical 4502.TJapan$69.8B+30%+6%18%51.0×3.7%+7.1%
WuXi AppTec 603259.SSChina$64.2B+40%+32%43%17.0×7.2%+22.3%
Bayer BAYN.DEGermany$60.3B+48%0%13%12.3×n/an/a
Galderma GALD.SWSwitzerland$51.9B+18%+16%19%45.7×18.0%+6.4%
Sun Pharmaceutical Industries SUNPHARMA.NSIndia$48.0B-1%+12%23%36.0×28.7%+11.7%
AstraZeneca AZN.LUnited Kingdom$278B-2%+5%23%17.6×14.4%+15.7%
Jiangsu Hengrui Pharmaceuticals 600276.SSChina$45.7B-13%+6%27%33.4×13.4%+2.7%
BeOne Medicines 688235.SSChina$45.5B+9%+25%18%59.7×19.1%+79.3%
Novartis NOVN.SWSwitzerland$285B+11%-4%30%17.5×1.6%-0.2%
Sandoz SDZ.SWSwitzerland$41.7B+26%+1%15%24.5×7.5%+0.4%
Otsuka Hldgs 4578.TJapan$39.9B+9%+11%18%16.8×1.6%+11.7%
Haleon HLN.LUnited Kingdom$39.6B0%+1%23%16.4×5.2%+2.2%

Sanofi bonds and credit

Sanofi has 15 bonds outstanding with $14.6B face value. The agencies rate it AA; its bonds trade like AAA. Weighted yield 3.73%, a spread of 41 bp over government bonds.

Every bond, yield and spread in the cockpit →

Questions

Who are Sanofi's main competitors?
Named competitors: Pfizer (PFE), Novartis (NOVN.SW), GSK (GSK.L), Merck & Co (MRK), Roche Holding (RO.SW). The cockpit's measured peer set (industry) also includes Bristol Myers Squibb (BMY), GSK (GSK.L), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Pfizer (PFE), Chugai Pharmaceutical (4519.T).
Is Sanofi expensive compared with its peers?
On forward p/e it trades at 9.7× against a peer median of 17.5×, 2nd cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about -5% a year for seven years (Req g). Recent delivered growth is +4%, so the hurdle is -9 pp: the price already allows for a slowdown.
How has Sanofi stock performed?
Over six months to 18 Nov 2026 the shares returned +13.0% against +9.1% for the median peer; over one year -0.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.